General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis

Advancing Care in Pediatric Plaque Psoriasis: Emerging Treatments and Management Strategies  : Episode 8

Opinion

Video

October 7, 2024

Exploring the Role of MOA and PDE4 Pathways in Pediatric Patients with Plaque Psoriasis

Author(s):

Karan Lal, DO, MS, FAADHelen T Shin, MD

Key Takeaways

PDE4 inhibitors modulate inflammatory responses by increasing intracellular cAMP levels, reducing pro-inflammatory cytokine production.
These agents offer a targeted approach, potentially minimizing side effects compared to traditional therapies.
PDE4 inhibitors hold promise for improving disease management and quality of life in pediatric patients with immune-mediated conditions.

Panelists discuss how phosphodiesterase-4 (PDE4) inhibitors, with their ability to modulate inflammatory pathways, hold promise as therapeutic targets for immune-mediated diseases like pediatric plaque psoriasis, offering unique benefits by potentially reducing inflammation with a favorable safety profile for pediatric patients.

EP: 1.Psychosocial Impact of Plaque Psoriasis in Younger Children

EP: 2.Overview of the Prevalence of Pediatric Plaque Psoriasis

EP: 3.Navigating Treatment Algorithms: Balancing Provider Preferences and Clinical Guidelines

EP: 4.Diagnostic Challenges in the Management of Pediatric Plaque Psoriasis

EP: 5.Adult vs Pediatric Plaque Psoriasis Treatment Challenges

EP: 6.Early Diagnosis and Management, Unmet Needs and Treatment Challenges in Pediatric Plaque Psoriasis

EP: 7.Examining Molecular Differences in PDE4 Inhibitors in Pediatric Patients with Plaque Psoriasis

Now Viewing

EP: 8.Exploring the Role of MOA and PDE4 Pathways in Pediatric Patients with Plaque Psoriasis

EP: 9.Provider Aspirations for Future Treatments and Clinical Investigations into Pediatric Plaque Psoriasis

Video content above is prompted by the following:

In light of the shifting treatment landscape, can you shed light on phosphodiesterase inhibitors-4 (PDE4), their nature, and why they hold promise as therapeutic targets for immune-mediated diseases like PP?
How might its mechanism of action provide unique benefits for pediatric patients?